Evidence map›Paper›PMID 42397844›Full record

ArticleVirulence2026

Encephalomyocarditis virus impairs the blood-brain barrier by degrading tight junction proteins via AKT3-dependent autophagic and apoptotic pathways.

Xueer Dou, Na Wang, Shuangshuang Yao, Xinrui Chen, Shasha Li, Jingying Xie, Xiangrong Li, Yanmei Yang, Yanqiao Wen, Adi Idris and 2 more

Abstract read
In one paragraph

Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xueer DouEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Na WangEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Shuangshuang YaoEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Xinrui ChenEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Shasha LiEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Jingying XieEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Xiangrong LiEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Yanmei YangEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Yanqiao WenEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.
Adi IdrisCentre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Australia.
Huixia LiEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.ORCID 0000-0001-8692-456X
Ruofei FengEngineering Research Center of Key Technology and Industrialization of Cell-Based Vaccine, Ministry of Education, Biomedical Research Center, Northwest Minzu University, Lanzhou, China.ORCID 0000-0001-9647-2827

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Encephalomyocarditis virus (EMCV) infection causes viral encephalitis; however, the mechanisms underlying blood-brain barrier (BBB) disruption remain poorly understood. Here, we demonstrate that EMCV actively replicates in mouse brain tissue, induces robust neuroinflammation characterized by elevated proinflammatory cytokines and chemokines, and markedly increases BBB permeability as evidenced by Evans blue and sodium fluorescein extravasation. Importantly, tight junction (TJ) proteins ZO-1 and Occludin are selectively degraded at the post-transcriptional level, whereas Claudin-5 expression remains stable. Consistently, in vitro BBB models confirmed EMCV traversal, reduced transendothelial electrical resistance, and TJ disruption. Mechanistically, EMCV induces biphasic PI3K/AKT modulation and specifically downregulates AKT3. Notably, AKT3 knockdown exacerbates both autophagy and apoptosis, thereby accelerating ZO-1 and Occludin degradation while promoting viral replication. Furthermore, pharmacological inhibition of autophagy (chloroquine) or apoptosis (Z-VAD-FMK) effectively rescues TJ proteins and reduces viral load. Interestingly, the Caspase-8 inhibitor Z-IETD-FMK provides the most robust protection, implicating the extrinsic apoptotic pathway as the dominant route. Collectively, EMCV sequentially activates non-redundant AKT3-dependent autophagic and apoptotic pathways to degrade TJ proteins, ultimately enabling viral traversal across the compromised BBB and offering therapeutic targets for viral encephalitis.

Indexed as

ApoptosisAutophagyBlood-Brain BarrierCardiovirus InfectionsEncephalomyocarditis virusProto-Oncogene Proteins c-aktTight Junction ProteinsAnimalsMiceMice, Inbred C57BLOccludinVirus ReplicationOccludinProto-Oncogene Proteins c-aktTight Junction ProteinsAKT3apoptosisautophagyblood-brain barrierEMCVtight junctions

Identifiers

PMID42397844
PMCPMC13336293

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.